Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304993 · ClinicalTrials.gov registry record · Phase 4
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
A Phase 4 study of Insulin Resistance and Metabolic Syndrome X, sponsored by Foundation Research, Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00304993: Completed Phase 4 study of Insulin Resistance and Metabolic Syndrome X, sponsored by Foundation Research, Florida.
NCT00304993 is a Phase 4 study of Insulin Resistance and Metabolic Syndrome X that has completed, run by Foundation Research, Florida. The registered enrollment target is 30 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304993, a Phase 4 study of Insulin Resistance and Metabolic Syndrome X, has completed, sponsored by Foundation Research, Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Lipid abnormalities in people with the Metabolic Syndrome (the Insulin Resistance Syndrome) are characterized by elevations in triglycerides and LDL cholesterol; low levels of HDL cholesterol; and small, dense LDL particles. Statins generally do not change LDL particle size, so often fenofibrate is added. This combination may still not be sufficient. Niacin is a common third drug added to the treatment regimen, but niacin can increase insulin resistance. This study compares niacin as a third drug to rosiglitazone, an insulin sensitizer.
Conditions Studied
Interventions
- DRUG rosiglitazone
- DRUG fenofibrate
- DRUG niacin
Study Locations (1)
Florida
- Foundation Research - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-01 |
| Est. Completion | 2005-02 |
| Phase | Phase 4 |
What the finished NCT00304993 record still lists
NCT00304993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 3 interventions - of which rosiglitazone is the first listed.
NCT00304993 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00304993 about?
NCT00304993 is a clinical study titled "Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia". Lipid abnormalities in people with the Metabolic Syndrome (the Insulin Resistance Syndrome) are characterized by elevations in triglycerides and LDL cholesterol; low levels of HDL cholesterol; and small, dense LDL particles. Statins generally do not change LDL particle size, so often fenofibrate is ...
What is the current status of trial NCT00304993?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2001-01. Estimated completion is 2005-02.
What conditions does trial NCT00304993 study?
This clinical trial studies the following conditions: Insulin Resistance, Metabolic Syndrome X.
What interventions are being tested in trial NCT00304993?
The interventions under investigation include: rosiglitazone (DRUG), fenofibrate (DRUG), niacin (DRUG).
Who is sponsoring clinical trial NCT00304993?
This trial is sponsored by Foundation Research, Florida, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00304993 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00304993's enrollment target sits among peer trials
30 89th of 120 higher than 29 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
COMPLETED · Phase 4
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
COMPLETED · Phase 4
-
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
COMPLETED · Phase 4
-
Pioglitazone in Patients With Mood Disorders
COMPLETED · Phase 4
-
Oral Contraceptives in the Metabolic Syndrome
COMPLETED · Phase 4
-
Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia